Related Experiment Video

Updated: Jun 19, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Association of the SDF1-3'A polymorphism with susceptibility to myocardial infarction in Chinese Han population

Bo Luan1, Yaling Han, Xiaolin Zhang

  • 1Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

Molecular Biology Reports
|October 13, 2009
PubMed

Insights

This study investigated the SDF1-3'A gene polymorphism (rs1801157) and its link to myocardial infarction (MI) in Chinese Han individuals. The SDF1-3'A polymorphism was associated with a reduced risk of MI.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Molecular Biology

Background:

  • Stromal cell-derived factor 1 (SDF-1) plays a role in atherosclerosis development.
  • Genetic variations may influence susceptibility to cardiovascular diseases like myocardial infarction (MI).

Purpose of the Study:

  • To examine the association between the SDF1-3'A polymorphism (rs1801157) and the risk of myocardial infarction (MI).
  • To investigate the genetic contribution of SDF-1 variations to MI in the Chinese Han population.

Main Methods:

  • Case-control study involving 560 MI patients and 532 healthy controls.
  • Genotyping of the SDF1-3'A polymorphism using polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP).
  • Statistical analysis including logistic regression to assess risk after controlling for conventional factors.

Main Results:

  • Significant differences in genotype distribution and allele frequencies of the SDF1-3'A polymorphism were found between MI patients and controls (P = 0.003 and P = 0.001).
  • Carriers of the A allele exhibited a significantly lower risk of MI compared to GG homozygotes (OR, 0.69; 95% CI, 0.52-0.92; adjusted P = 0.007).

Conclusions:

  • The SDF1-3'A polymorphism is significantly associated with myocardial infarction risk in the Chinese Han population.
  • This finding suggests a potential genetic marker for MI susceptibility within this demographic group.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...